What was studied?
A randomized placebo-controlled phase 3 study examined retatrutide in adults with both obesity and type 2 diabetes.
What did the researchers report?
Retatrutide produced greater weight reductions than placebo and improved glycemic measures. The study also reported adverse events within the defined trial population.
What are the limits?
Interpret the reported effect estimates and tolerability within this trial's estimands and eligibility criteria. Results concern a defined investigational formulation, not interchangeable research products.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.